

**MODELLO PER IL
CURRICULUM VITAE****INFORMAZIONI PERSONALI**

Nome	Donatella Del Bufalo
Data di nascita	██████████
Qualifica	Dirigente Biologo
Amministrazione	Istituti Fisioterapici Ospitalieri - IRCCS Istituto Nazionale Tumori Regina Elena
Incarico attuale	Ricercatore Senior
Numero telefonico dell'ufficio	0652662575
Fax dell'ufficio	0652662013
E-mail istituzionale	donatella.delbufalo@ifo.gov.it

**TITOLI DI STUDIO E
PROFESSIONALI ED ESPERIENZE
LAVORATIVE**

Titolo di studio	1985 - Laurea in Scienze Biologiche presso l'Università "La Sapienza" di Roma, votazione 110/110
Altri titoli di studio e professionali	1986 - Abilitazione professione Biologo, 1991 - Specializzazione in Patologia Clinica indirizzo tecnico presso l'Università "La Sapienza" di Roma, votazione 70/70 con lode
Esperienze professionali (incarichi ricoperti)	Responsabile scientifico di progetti finanziati dal Ministero della Salute, dall'Associazione Italiana per la Ricerca sul Cancro e dal Consiglio Nazionale delle Ricerche. Dal 1990 al 1991 Visiting Molecular and Cellular Immunology Laboratory diretto dal Dr. H.A. Young (NCI Frederick) Dal 1992 al 1995 Professore a contratto presso l'Università di Roma "La Sapienza", Corso per Tecnici di Laboratorio Biomedico e Biotecnologie, Insegnamento di Immunologia Molecolare. Dal 1998 ad oggi tutor di borsisti vincitori di bandi dell'Associazione Italiana per la Ricerca sul Cancro Dal 2000-2004 Membro della Study Section dall'Associazione Italiana per la Ricerca sul Cancro. Dal 2000 ad oggi tutor di tesisti del corso di laurea in Scienze Biologiche e Chimica e Tecnologie Farmaceutiche e di dottorandi presso le Università degli Studi di Roma "Sapienza" e "Roma Tre" e l'Università degli Studi di Siena. Dal 2006 membro del Consiglio Direttivo della Società Italiana di Cancerologia, dal 2008 al 2009 segretario del Consiglio Direttivo della Società Italiana di Cancerologia. Dal 2013 al 2016 membro del Comitato Esecutivo European Association for Cancer Research Dal 2013 ad oggi tutor di borsisti vincitori di bandi della Fondazione Umberto Veronesi 2015 Advisory board of Cancer Research award assignment Pezcoller Foundation/American Association for Cancer Research (AACR) 2016 Advisory board of award for Cancer Researcher Pezcoller Foundation/European Association for Cancer Research (EACR)
Capacità linguistiche	Ottima conoscenza dell'inglese parlato e scritto. Discreta conoscenza del francese parlato e scritto.
Capacità nell'uso delle tecnologie	Adeguate.
Altro (partecipazione a convegni e seminari, pubblicazioni, collaborazioni a riviste, ecc. ed	Revisione di manoscritti per riviste scientifiche internazionali. Pubblicazioni di capitoli di libri. Organizzazione congressi scientifici internazionali

ogni altra informazione che il dirigente ritiene di dover pubblicare)	<ul style="list-style-type: none"> - Hypoxia and Cancer, Roma, 6 ottobre 2006 - 52° Congresso Nazionale della Società Italiana di Cancerologia, Roma, 4-7 ottobre 2010
---	--

Pubblicazioni

1. Bosco MC, D'Orazi G, **Del Bufalo D**. Targeting hypoxia in tumor: a new promising therapeutic strategy. *J Exp Clin Cancer Res*. 2020 Jan 10;39(1):8. doi: 10.1186/s13046-019-1517-0.
2. Mottini C, Tomihara H, Carrella D, Lamolinara A, Iezzi M, Huang JK, Amoreo CA, Buglioni S, Manni I, Robinson FS, Minelli R, Kang Y, Fleming JB, Kim MP, Bristow CA, Trisciuglio D, Iuliano A, **Del Bufalo D**, Di Bernardo D, Melisi D, Draetta GF, Ciliberto G, Carugo A, Cardone L. Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS-Dependent Pancreatic Ductal Adenocarcinoma. *Cancer Res*. 2019 Nov 1;79(21):5612-5625. doi: 10.1158/0008-5472.CAN-19-0187.
3. Trisciuglio D, Di Martile M, **Del Bufalo D**. Emerging Role of Histone Acetyltransferase in Stem Cells and Cancer. *Stem Cells Int*. 2018 Dec 16;2018:8908751. doi: 10.1155/2018/8908751.
4. D'Aguanno S, Valentini E, Tupone MG, Desideri M, Di Martile M, Spagnuolo M, Buglioni S, Ercolani C, Falcone I, De Dominicis M, Milella M, Rizzo MG, Calabretta B, Cota C, Anichini A, Trisciuglio D, **Del Bufalo D**. Semaphorin 5A drives melanoma progression: role of Bcl-2, miR-204 and c-Myb. *J Exp Clin Cancer Res*. 2018 Nov 19;37(1):278. doi: 10.1186/s13046-018-0933-x.
5. Iachettini S, Trisciuglio D, Rotili D, Lucidi A, Salvati E, Zizza P, Di Leo L, **Del Bufalo D**, Ciriolo MR, Leonetti C, Steegborn C, Mai A, Rizzo A, Biroccio A. Pharmacological activation of SIRT6 triggers lethal autophagy in human cancer cells. *Cell Death Dis*. 2018 Sep 24;9(10):996. doi: 10.1038/s41419-018-1065-0.
6. Del Curatolo A, Conciatori F, Cesta Incani U, Bazzichetto C, Falcone I, Corbo V, D'Agosto S, Eramo A, Sette G, Sperduti I, De Luca T, Marabese M, Shirasawa S, De Maria R, Scarpa A, Broggin M, **Del Bufalo D**, Cognetti F, Milella M, Ciuffreda L. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models. *J Exp Clin Cancer Res*. 2018 Jul 9;37(1):140. doi: 10.1186/s13046-018-0820-5.
7. Loria R, Laquintana V, Bon G, Trisciuglio D, Frapolli R, Covello R, Amoreo CA, Ferraresi V, Zoccali C, Novello M, **Del Bufalo D**, Milella M, Biagini R, D'Incalci M, Falcioni R. HMGA1/E2F1 axis and NFkB pathways regulate LPS progression and trabectedin resistance. *Oncogene*. 2018 Jul 6. doi: 10.1038/s41388-018-0394-x.
8. Di Martile M, Desideri M, Tupone MG, Buglioni S, Antoniani B, Mastroiorio C, Falcioni R, Ferraresi V, Baldini N, Biagini R, Milella M, Trisciuglio D, **Del Bufalo D**. Histone deacetylase inhibitor ITF2357 leads to apoptosis and enhances doxorubicin cytotoxicity in preclinical models of human sarcoma. *Oncogenesis*. 2018 Feb 23;7(2):20. doi: 10.1038/s41389-018-0026-x.
9. Trisciuglio D, Tupone MG, Desideri M, Di Martile M, Gabellini C, Buglioni S, Pallocca M, Alessandrini G, D'Aguanno S, **Del Bufalo D**. BCL-XL overexpression promotes tumor progression-associated properties. *Cell Death Dis*. 2017 Dec 13;8(12):3216. doi: 10.1038/s41419-017-0055-y.
10. Monaco G, La Rovere R, Karamanou S, Welkenhuyzen K, Ivanova H, Vandermarliere E, Di Martile M, **Del Bufalo D**, De Smedt H, Parys JB, Economou A, Bultynck G. A double point mutation at residues Ile14 and Val15 of Bcl-2 uncovers a role for the BH4 domain in both protein stability and function. *FEBS J*. 2018 Jan;285(1):127-145. doi: 10.1111/febs.14324.
11. Gabellini C, Gómez-Abenza E, Ibáñez-Molero S, Tupone MG, Pérez-Oliva AB, de Oliveira S, **Del Bufalo D**, Mulero V. Interleukin 8 mediates bcl-xL-induced enhancement of human melanoma cell dissemination and angiogenesis in a zebrafish xenograft model. *Int J Cancer*. 2018 Feb 1;142(3):584-596. doi: 10.1002/ijc.31075.
12. Ferrara M, Sessa G, Fiore M, Bernard F, Asteriti IA, Cundari E, Colotti G, Ferla S, Desideri M, Buglioni S, Trisciuglio D, **Del Bufalo D**, Brancale A, Degrassi F. Small molecules targeted to the microtubule-Hec1 interaction inhibit cancer cell growth through microtubule stabilization. *Oncogene*. 2018 Jan 11;37(2):231-240. doi: 10.1038/onc.2017.320.
13. Fianco G, Mongiardi MP, Levi A, De Luca T, Desideri M, Trisciuglio D, **Del Bufalo D**, Cinà I, Di Benedetto A, Mottolese M, Gentile A, Centonze D, Ferrè F, Barilà D. Caspase-8 contributes to angiogenesis and chemotherapy resistance in glioblastoma. *Elife*. 2017 Jun 8;6. pii: e22593. doi: 10.7554/eLife.22593.
14. Noto A, De Vitis C, Pisanu ME, Roscilli G, Ricci G, Catizone A, Sorrentino G, Chianese G, Tagliatela-Scafati O, Trisciuglio D, **Del Bufalo D**, Di Martile M, Di Napoli A, Ruco L, Costantini S, Jakopin Z, Budillon A, Melino G, Del Sal G, Ciliberto G, Mancini R. Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ. *Oncogene*. 2017 Aug 10;36(32):4573-4584. doi: 10.1038/onc.2017.75.

15. Palanisamy SK, Trisciuglio D, Giacobbe S, Zwergl C, Mai A, **Del Bufalo D**, Quinn RJ. Metabolite profiling of ascidian *Styela plicata* using LC-MS with multivariate statistical analysis and their Anti-tumor activity *J Enzym Inhib Med Ch*. 2017 Dec;32(1):614-623. doi: 10.1080/14756366.2016.1266344.
16. De Luca T, Pelosi A, Trisciuglio D, D'Aguanno S, Desideri M, Farini V, Di Martile M, Bellei B, Tupone MG, Candiloro A, Regazzo G, Rizzo MG, **Del Bufalo D**. miR-211 and MITF modulation by Bcl-2 protein in melanoma cells. *Mol Carcinog*. 2016 Dec;55(12):2304-2312.
17. **Del Bufalo D**, Degrassi F. Erratum: Kinetochore-microtubule attachments in cancer therapy *Oncoscience*. 2016 Feb 4;3(1):49.
18. Di Martile M, **Del Bufalo D**, Trisciuglio D. The multifaceted role of lysine acetylation in cancer: prognostic biomarker and therapeutic target. *Oncotarget*. 2016 Jun 14.
19. Di Martile M, Desideri M, De Luca T, Gabellini C, Buglioni S, Eramo A, Sette G, Milella M, Rotili D, Mai A, Carradori S, Secci D, De Maria R, **Del Bufalo D**, Trisciuglio D. Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells. *Oncotarget*. 2016 Mar 8;7(10):11332-48.
20. Trisciuglio D, Desideri M, Farini V, De Luca T, Di Martile M, Tupone MG, Urbani A, D'Aguanno S, **Del Bufalo D**. Affinity purification-mass spectrometry analysis of bcl-2 interactome identified SLIRP as a novel interacting protein. *Cell Death Dis*. 2016 Feb 11;7:e2090.
21. Favia A, Pafumi I, Desideri M, Padula F, Montesano C, Passeri D, Nicoletti C, Orlandi A, **Del Bufalo D**, Sergi M, Ziparo E, Palombi F, Filippini A. NAADP-Dependent Ca(2+) Signaling Controls Melanoma Progression, Metastatic Dissemination and Neovascularization. *Sci Rep*. 2016 Jan 6;6:18925
22. Valente S, Mellini P, Spallotta F, Carafa V, Nebbioso A, Polletta L, Carnevale I, Saladini S, Trisciuglio D, Gabellini C, Tardugno M, Zwergl C, Cencioni C, Atlante S, Moniot S, Steegborn C, Budriesi R, Tafani M, **Del Bufalo D**, Altucci L, Gaetano C, Mai A. 1,4-Dihydropyridines Active on the SIRT1/AMPK Pathway Ameliorate Skin Repair and Mitochondrial Function and Exhibit Inhibition of Proliferation in Cancer Cells. *J Med Chem*. 2016 Feb 25;59(4):1471-91
23. **Del Bufalo D**, Degrassi F. Kinetochore-microtubule attachments in cancer therapy. *Oncoscience* 2015.
24. Mariano G, Ricciardi MR, Trisciuglio D, Zampieri M, Ciccarone F, Guastafierro T, Calabrese R, Valentini E, Tafuri A, **Del Bufalo D**, Caiafa P, Reale A. PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression. *Oncotarget*. 2015 Jun 20;6(17):15008-21.
25. Gambarà G, Desideri M, Stoppacciaro A, Padula F, De Cesaris P, Starace D, Tubaro A, **Del Bufalo D**, Filippini A, Ziparo E, Riccioli A. LR3 engagement induces IRF-3-dependent apoptosis in androgen-sensitive prostate cancer cells and inhibits tumour growth in vivo. *J Cell Mol Med*. 2015 Feb;19(2):327-39.
26. Favia A, Desideri M, Gambarà G, D'Alessio A, Ruas M, Esposito B, **Del Bufalo D**, Parrington J, Ziparo E, Palombi F, Galione A, Filippini A. VEGF-induced neoangiogenesis is mediated by NAADP and two-pore channel-2-dependent Ca2+ signaling. *Proc Natl Acad Sci U S A*. 2014 Nov 4;111(44):E4706-15.
27. **Del Bufalo D**, Desideri M, De Luca T, Di Martile M, Gabellini C, Monica V, Busso S, Eramo A, De Maria R, Milella M, Trisciuglio D. Histone deacetylase inhibition synergistically enhances pemetrexed cytotoxicity through induction of apoptosis and autophagy in non-small cell lung cancer. *Mol Cancer*. 2014 Oct 9;13:230
28. Orticello M, Fiore M, Totta P, Desideri M, Barisic M, Passeri D, Lenzi J, Rosa A, Orlandi A, Malato H, **Del Bufalo D**, Degrassi F. N-terminus-modified Hec1 suppresses tumour growth by interfering with kinetochore-microtubule dynamics. *Oncogene*. 2014 Aug 18.
29. Doldo E, Costanza G, Ferlosio A, Passeri D, Bernardini S, Scioli MG, Mazzaglia D, Agostinelli S, **Del Bufalo D**, Czernobilsky B, Orlandi A. CRBP-1 expression in ovarian cancer: a potential therapeutic target. *Anticancer Res*. 2014 Jul;34(7):3303-12.
30. Valente S, Trisciuglio D, De Luca T, Nebbioso A, Labella D, Lenoci A, Bigogno C, Dondio G, Miceli M, Brosch G, **Del Bufalo D**, Altucci L, Mai A. 1,3,4-oxadiazole-containing histone deacetylase inhibitors: anticancer activities in cancer cells. *J Med Chem*. 2014 Jul 24;57(14):6259-65.
31. Pelosi A, Careccia S, Sagrestani G, Nanni S, Manni I, Schinzari V, Martens JH, Farsetti A, Stunnenberg HG, Gentileschi MP, **Del Bufalo D**, De Maria R, Piaggio G, Rizzo MG. Dual promoter usage as regulatory mechanism of *let-7c* expression in leukemic and solid tumors. *Mol Cancer Res*. 2014 Jun;12(6):878-89.
32. Gabellini C, De Luca T, Trisciuglio D, Desideri M, Di Martile M, Passeri D, Candiloro A, Biffoni M, Rizzo MG, Orlandi A, **Del Bufalo D**. BH4 domain of bcl-2 protein is required for its proangiogenic function under hypoxic condition. *Carcinogenesis*. 2013 Nov;34(11):2558-67.
33. Scarpino S, Duranti E, Giglio S, Di Napoli A, Galafate D, **Del Bufalo D**, Desideri M, Socciarelli F, Stoppacciaro A, Ruco L. Papillary carcinoma of the thyroid: high expression of COX-2 and low expression of KAI-1/CD82 are associated with increased tumor invasiveness. *Thyroid*. 2013 Sep;23(9):1127-37.
34. Valente S, Trisciuglio D, Tardugno M, Benedetti R, Labella D, Secci D, Mercurio C, Boggio R, Tomassi S, Di Maro S, Novellino E, Altucci L, **Del Bufalo D**, Mai A, Cosconati S. tert-Butylcarbamate-Containing Histone Deacetylase Inhibitors: Apoptosis Induction, Cytodifferentiation, and Antiproliferative Activities in Cancer Cells. *ChemMedChem*. 2013 May;8(5):800-11.


35. Trisciuglio D, De Luca T, Desideri M, Passeri D, Gabellini C, Scarpino S, Liang C, Orlandi A, **Del Bufalo D**. Removal of the BH4 domain from Bcl-2 protein triggers an autophagic process that impairs tumor growth. *Neoplasia*. 2013 Mar;15(3):315-27.
36. Ragazzoni Y, Desideri M, Gabellini C, De Luca T, Carradori S, Secci D, Nescatelli R, Candiloro A, Condello M, Meschini S, **Del Bufalo D**, Trisciuglio D. The thiazole derivative CPTH6 impairs autophagy. *Cell Death Dis*. 2013 Mar 7;4:e524
37. Maresca G, Natoli M, Nardella M, Arisi I, Trisciuglio D, Desideri M, Brandi R, D'Aguzzo S, D'Onofrio M, Urbani A, **Del Bufalo D**, Felsani A, D'Agnano I. LMNA knock-down affects differentiation and progression of human neuroblastoma cells. *Plos One* 7(9):e45513, 2012.
38. Caporali S, Alvino E, Levati L, Esposito AI, Ciomei M, Brasca MG, **Del Bufalo D**, Desideri M, Bonmassar E, Pfeffer U, D'Atri S. Down-regulation of the PTTG1 proto-oncogene contributes to the melanoma suppressive effects of the cyclin-dependent kinase inhibitor PHA-848125. *Biochem Pharmacol*. 84(5):598-611, 2012.
39. Ricciardi MR, Scerpa MC, Bergamo P, Ciuffreda L, Petrucci MT, Chiaretti S, Tavolaro S, Mascolo MG, Abrams SL, Steelman LS, Tsao T, Marchetti A, Konopleva M, **Del Bufalo D**, Cognetti F, Foà R, Andreeff M, McCubrey JA, Tafuri A, Milella M. Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies. *J Mol Med (Berl)*. 90(10):1133-44, 2012.
40. Ciuffreda L, Di Sanza C, Cesta Incani U, Eramo A, Desideri M, Biagioni F, Passeri D, Falcone I, Sette G, Bergamo P, Anichini A, Sabapathy K, McCubrey JA, Ricciardi MR, Tafuri A, Blandino G, Orlandi A, De Maria R, Cognetti F, **Del Bufalo D**, Milella M. The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. *J Mol Med (Berl)*. 90(6):667-79, 2012.
41. Trisciuglio D, Ragazzoni Y, Pelosi A, Desideri M, Carradori S, Gabellini C, Maresca G, Nescatelli R, Secci D, Bolasco A, Bizzarri B, Cavaliere C, D'Agnano I, Filetici P, Ricci-Vitiani L, Rizzo MG, **Del Bufalo D**. CPTH6, a thiazole-derivative, induces histone hypoacetylation and apoptosis in human leukemia cells. *Clin Cancer Res*. 18(2):475-86, 2012.
42. Azzariti A, Bocci G, Porcelli L, Fioravanti A, Sini P, Simone GM, Quatrone AE, Chiarappa P, Mangia A, Sebastian S, **Del Bufalo D**, Del Tacca M, Paradiso A. Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer. *Br J Cancer*. 104(5):769-80, 2011.
43. **Del Bufalo D**, Bagnato A, Fusco A, Milella M. Lost in translation: bridging the gap between cancer research and effective therapies. *Cell Death Differ*. 18(6):1082-4, 2011.
44. Trisciuglio D, Gabellini C, Desideri M, Ragazzoni Y, De Luca T, Ziparo E, **Del Bufalo D**. Involvement of BH4 domain of bcl-2 in the regulation of HIF-1-mediated VEGF expression in hypoxic tumor cells. *Cell Death Differ*. 18(6):1024-35, 2011.
45. Trisciuglio D, Gabellini C, Desideri M, Ziparo E, Zupi G, **Del Bufalo D**. Bcl-2 regulates HIF-1 α protein stabilization in hypoxic melanoma cells via the molecular chaperone HSP90. *PLoS One*. 5(7):e11772, 2010.
46. Paone A, Galli R, Gabellini C, Lukashchuk D, Starace D, Goralich A, De Cesaris P, Ziparo E, **Del Bufalo D**, Sitkovsky MV, Filippini A, Riccioli A. Toll-like receptor 3 regulates angiogenesis and apoptosis in prostate cancer cell lines through hypoxia-inducible factor 1 α . *Neoplasia*. 12(7):539-49, 2010.
47. Fontemaggi G, Dell'orso S, Trisciuglio D, Shay T, Melucci E, Fazi F, Terrenato I, Mottolese M, Muti P, Domany E, **Del Bufalo D**, Strano S, Blandino G. The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. *Nat Struct Mol Biol*. 16(10):1086-93., 2009.
48. Gabellini C, Trisciuglio D, Desideri M, Candiloro A, Ragazzoni Y, Orlandi A, Zupi G and **Del Bufalo D**. Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression. *Eur J Cancer*. 45(14):2618-27, 2009
49. Ciuffreda L, **Del Bufalo D**, Desideri M, Di Sanza C, Stoppacciaro A, Ricciardi MR, Chiaretti S, Tavolato S, Benassi B, Bellicosa A, Foà R, Tafuri A, Cognetti F, Anichini A, Zupi G, Milella M. Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations. *Neoplasia*. 11(8):720-731, 2009
50. Gabellini C, Castellini L, Trisciuglio D, Kracht M, Zupi G, **Del Bufalo D**. Involvement of Nuclear Factor- κ B in bcl-xL-induced interleukin 8 expression in glioblastoma. *J Neurochem*. 107:871-82, 2008.
51. Trisciuglio D, Uranchimeg B, Cardellino II JH, Meragelman TL, Matsunaga S, Fusetani N, **Del Bufalo D**, Shoemaker RH, Melillo G. Induction of Apoptosis in Human Cancer Cells by Candidaspongolide, a Novel Sponge Polyketide. *J Natl Cancer Inst*. 100:1-14, 2008.
52. Giorgini S, Trisciuglio D, Gabellini C, Desideri M, Castellini L, Colarossi C, Zangemeister-Wittke U, Zupi G, **Del Bufalo D**. Modulation of bcl-xL in Tumor Cells Regulates Angiogenesis through CXCL8 Expression. *Mol Cancer Res*. 5:761-71, 2007.
53. Gabellini C, **Del Bufalo D**, Zupi G. Involvement of RB gene family in tumor angiogenesis. *Oncogene Review*. 25:5326-32, 2006.
54. **Del Bufalo D**, Ciuffreda L, Trisciuglio D, Desideri M, Cognetti F, Zupi G, Milella M. Anti angiogenic Potential of the Mammalian Target of Rapamycin Inhibitor Temsirolimus. *Cancer Res*. 66:5549-54, 2006.

55. Trisciuglio D, Iervolino A, Zupi G, **Del Bufalo D**. Involvement of PI3K and MAPK Signaling in bcl-2-induced Vascular Endothelial Growth Factor Expression in Melanoma Cells. *Mol Biol Cell*. 16:4153-62, 2005.
56. Trisciuglio D, Desideri M, Ciuffreda L, Mottolese M, Ribatti D, Vacca A, Del Rosso M, Marcocci L, Zupi G, **Del Bufalo D**. Bcl-2 overexpression in melanoma cells increases tumor progression-associated properties and in vivo tumor growth *J Cell Physiol*. 205:414-21, 2005.
57. **Del Bufalo D**, Rizzo A, Trisciuglio D, Cardinali G, Torrissi MR, Zangemeister-Wittke U, Zupi G, Biroccio A. Involvement of hTERT in apoptosis induced by interference with Bcl-2 expression and function. *Cell Death Differ*. 12:1429-38, 2005.
58. De Cesare M, Perego P, Righetti SC, Pratesi G, Carenini N, Rivoltini L, Zupi G, **Del Bufalo D**, Balsari A, Zunino F. Enhanced antitumour efficacy of gimatecan in combination with Bcl-2 antisense oligonucleotide in human melanoma xenografts. *Eur J Cancer*. 41:1213-22, 2005.
59. Milella M, Trisciuglio D, Bruno T, Ciuffreda L, Mottolese M, Cianciulli A, Cognetti F, Zangemeister-Wittke U, **Del Bufalo D**, Zupi G. Trastuzumab Downregulates Bcl-2 Expression And Potentiates Apoptosis Induction by Bcl-2/Bcl-XL Bispecific Antisense Oligonucleotides in HER-2 Gene Amplified Breast Cancer Cells. *Clin Cancer Res*. 10:7747-56, 2004.
60. **Del Bufalo D**, Trisciuglio D, Scarsella M, D'Amati G, Candiloro A, Iervolino A, Leonetti C, Zupi G. Lonidamine shows inhibition of critical steps in angiogenesis progression. *Neoplasia*. 6:513-22, 2004.
61. Trisciuglio D, Iervolino A, Candiloro A, Fibbi G, Fanciulli M, Zangemeister-Wittke U, Zupi G, **Del Bufalo D**. Bcl-2 induction of urokinase plasminogen activator receptor expression in human cancer cells through Sp1 activation: Involvement of Erk1/Erk2 activity. *J Biol Chemistry*. 279:6737-45, 2004.
62. **Del Bufalo D**, Trisciuglio D, Scarsella M, Zangemeister-Wittke U, Zupi G. Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity. *Oncogene*. 22:8441-7, 2003.
63. Biroccio A, Gabellini C, Amodei S, Benassi B, **Del Bufalo D**, Elli R, Antonelli A, D'Incalci M, Zupi G. Telomere Dysfunction Increases Cisplatin and Ecteinascidin-743 Sensitivity of Melanoma Cells. *Mol Pharmacol*. 63 :632-8, 2003.
64. **Del Bufalo D**, Biroccio A, Trisciuglio D, Bruno T, Floridi A, Aquino A, Zupi G. Bcl-2 has differing effects on the sensitivity of breast cancer cells depending on the antineoplastic drug used. *Eur J Cancer*. 38:2455-62, 2002.
65. Iervolino A, Trisciuglio D, Ribatti D, Candiloro A, Biroccio A, Zupi G, **Del Bufalo D**. Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity. *Faseb J*. 16:1453-5, 2002.
66. Biroccio A, Amodei S, Benassi B, Scarsella M, Cianciulli A, Mottolese M, **Del Bufalo D**, Leonetti C, Zupi G. Reconstitution of hTERT restores tumorigenicity in melanoma-derived c-myc low-expressing clones. *Oncogene*. 21:3011-9, 2002.
67. Ciardiello F, Caputo R, Borriello G, **Del Bufalo D**, Biroccio A, Zupi G, Bianco AR, Tortora G. ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhance taxane activity in bcl-2 overexpressing, multidrug-resistance MCF-7 ADR human breast cancer cells. *Int J Cancer*. 98:463-9, 2002.
68. **Del Bufalo D**, Di Castro V, Biroccio A, Salani D, Rosanò L, Spinella F, Bagnato A. Endothelin-1 protects ovarian carcinoma cells from paclitaxel-induced apoptosis. *Clin Science*. (Lond). 103 Suppl 48:302S-05S, 2002.
69. **Del Bufalo D**, Di Castro V, Biroccio A, Varmi M, Salani D, Rosanò L, Trisciuglio D, Spinella F, Bagnato A. Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation. *Mol Pharmacol*. 61:524-32, 2002.
70. Ricca A, Biroccio A, Trisciuglio D, Cippitelli M, Zupi G, **Del Bufalo D**. RelA over-expression reduces tumorigenicity and activates apoptosis in human cancer cells. *Br J Cancer*. 85:1914-21, 2001.
71. **Del Bufalo D**, Trisciuglio D, Biroccio A, Marcocci L, Buglioli S, Candiloro A, Scarsella M, Leonetti C, Zupi G. Bcl-2 overexpression decrease BCNU sensitività of a human glioblastoma line through enhancement of catalane activity. *J Cell Biochem*. 83:473-83, 2001.
72. **Del Bufalo D**, Trisciuglio D, Biroccio A. Role of bcl-2 on tumor progression, metastatization and angiogenesis. *Recent Research Developments in Cancer* 3: 411-523, 2001.
73. Biroccio A, Benassi B, Amodei S, Gabellini C, **Del Bufalo D**, Zupi G. c-myc down-regulation increases suceptibility to cisplatin through ROS-mediated apoptosis in M14 human melanoma cells. *Mol Pharmacol*. 60:174-82, 2001.
74. Meschini S, Calcabrini A, Monti E, **Del Bufalo D**, Stringaro A, Dolfini E, Arancia G. Intracellular P-glycoprotein expression is associated with the intrinsic multidrug resistance phenotype in human colon adenocarcinoma cells. *Int J Cancer*. 87:615-28, 2000.
75. Biroccio A, Candiloro A, Mottolese M, Sapora O, Albini A, Zupi G, **Del Bufalo D**. Bcl-2 overexpressiopl and hypoxia synergistically act to modulate vascular endothelial growth expression and in vivo angiogenesis in a breast carcinoma line. *Faseb J*. 14:652-60, 2000.
76. Ricca A, Biroccio A, **Del Bufalo D**, Mackay AR, Santoni A, Cippitelli M. Bcl-2 overexpression enhances NF-kB activity and induces mmp-9 transcription in human MCF7 ADR breast cancer cells. *Int J Cancer*. 86:188-96, 2000.

77. Leonetti C, Biroccio A, Candiloro A, Citro G, Fornari C, Mottolese M, **Del Bufalo D**, Zupi G. Increase of cisplatin sensitivity by c-myc antisense oligodeoxynucleotides in a human metastatic melanoma inherently resistant to cisplatin. *Clin Cancer Res.* 5:2588-95, 1999.
78. Biroccio A, **Del Bufalo D**, Ricca A, D'Angelo C, D'Orazi G, Sacchi A, Soddu S, Zupi G. Increase of BCNU sensitivity by wt-p53 gene therapy in a glioblastoma line depends on the administration schedule. *Gene Ther.* 6:1064-72, 1999.
79. Biroccio A, **Del Bufalo D**, Fanciulli M, Bruno T, Zupi G, Floridi A. Bcl-2 inhibits mitochondrial metabolism and lonidamine-induced apoptosis in adriamycin-resistant MCF7 cells. *Int J Cancer.* 82:125-30, 1999.
80. Molinari A, Calcabrini A, Meschini S, Stringaro A, **Del Bufalo D**, Cianfriglia M, Arancia G. Detection of p-glycoprotein in the golgi apparatus of drug-untreated human melanoma cells. *Int J Cancer.* 75:885-93, 1998.
81. **Del Bufalo D**, Leonetti C, Bucci B, Amedeo C, Falcioni R, Biroccio A, Zupi G. N-methylformamide induces changes on adhesive properties and lung-colonising potential of M14 melanoma cells. *Br J Cancer.* 77: 210-5, 1998.
82. Biroccio A, **Del Bufalo D**, Zupi G. *Biologia delle Metastasi. Ricerca di Base in Urologia*, vol. II: 23-29, 1997
83. **Del Bufalo D**, Biroccio A, Leonetti C, Zupi G. Bcl-2 overexpression enhances the metastatic potential of a human breast cancer line. *Faseb J.* 11: 947-53, 1997.
84. **Del Bufalo D**, Biroccio A, Soddu S, Laudonio N, D'Angelo C, Sacchi A, Zupi G. Lonidamine induces apoptosis in drug-resistant cells independently of the p53 gene. *J Clin Invest.* 98: 1165-73, 1996.
85. **Del Bufalo D**, Cucco C, Citro G, D'Agnano I, Benassi M, Geiser T, Zon G, Calabretta B, Zupi G. Effect of cisplatin and c-myc antisense phosphorothioate oligodeoxynucleotides combination on a human colon carcinoma cell line in vitro and in vivo. *Br J Cancer.* 74:387-93, 1996.
86. Zupi G, Molinari A, D'Agnano I, Meschini S. **Del Bufalo D**, Matarrese P, Candiloro A, Calcabrini A, Citro G, Arancia G. Adriamycin resistance induced by lonidamine in human breast cancer cells. *Anticancer Res.* 15:2469-78, 1995.
87. Scotlandi K, Serra M, Manara MC, Lollini PL, **Del Bufalo D**, Maurici D, Baldini N. Pretreatment of human osteosarcoma cells with N-Methylformamide enhances P-glycoprotein expression and resistance to doxorubicin. *Int J Cancer.* 58:95-101, 1994.
88. **Del Bufalo D**, Bucci B, D'Agnano I, Zupi G. N-Methyl-formamide as a potential therapeutic approach in colon cancer. *Colon and Rectum Disease* 37(suppl): S133-S137, 1994.
89. **Del Bufalo D**, Zupi G. In vitro potentiation of epirubicin activity by lonidamine in a human breast cancer cell line. *Int J Oncol.* 4:737-40, 1994.
90. **Del Bufalo D**, Zupi G, D'Agnano I, Falcioni R, Marangolo M, Sacchi A. Growth inhibition of HT29 cells exposed to N-methylformamide correlates with altered expression of 6/4 integrin. *Int J Oncol.* 1:97-105, 1992.
91. **Del Bufalo D**, Marangolo M, Zupi G. Therapeutic potential of differentiating agents in colon cancer treatment. *J Surgical Onco.* 2:14-5, 1991.
92. Laudonio N, Marcocci L, Arancia A, Calcabrini A, **Del Bufalo D**, Greco C, Zupi G, Mavelli I, Pedersen JZ, Bozzi A, Mondovì B. Enhancement of hyperthermic damage on M14 melanoma cells by liposome pretreatment. *Cancer Res.* 50:5119-26, 1990.
93. Greco C, **Del Bufalo D**, Giannarelli D, Marangolo M, Fuggetta MP, Bonmassar E, Zupi G. N-Methylformamide affects spontaneous metastases of 3LL lines and increase natural killer activity of tumor-bearing mice. *Clin Exper Metastasis.* 8:153-63, 1990.
94. Leonetti C, D'Agnano I, **Del Bufalo D**, Carapella C, Zupi G. Human neural lines as experimental models for biological and chemosensitivity studies. *J Neurosurgical Sciences.* 33:39-42, 1989.

DICHIARAZIONE

Il sottoscritto è a conoscenza che, ai sensi degli articoli 46, 47 e 49 del D.P.R. 445/2000 e consapevole che chiunque rilascia dichiarazioni mendaci, forma atti falsi o ne fa uso è punito ai sensi del codice penale e delle leggi speciali in materia. Inoltre, il sottoscritto autorizza al trattamento dei dati personali, ivi compresi quelli sensibili, ai sensi e per gli effetti del decreto legge 196/2003.
Roma, 24/01/2020



Dr.ssa Donatella Del Bufalo